ABOUT

Bridge Biotherapeutics, Inc. is a virtually-operated, venture-backed
clinical stage global biotech company, headquartered in Seongnam, Korea
with its subsidiary at JLABS@TMC, engaged in the development of novel therapeutics,
focusing on therapeutic areas of high unmet medical needs,
such as ulcerative colitis, fibrotic diseases, and cancers.

아이콘

Management

The management team at Bridge Biotherapeutics, Inc. has in-depth experience in the global pharmaceutical industry. With their multiple decades of combined professional experience, The Bridge Biotherapeutics team has been successfully developing early stage assets to clinic and is expected to expand and strengthen its pipeline to address global unmet medical needs.

  • 이정규 이사님 사진 James Jungkue Lee

    CEO

    more
    James Jungkue Lee founded Bridge Biotherapeutics, Inc. in 2015 and currently serves as CEO. After receiving his M.S. in Structural Biology from Seoul National University, he took various roles in research, research planning, and business development at LG Chem. James co-founded Crystal Genomics and led fundraising and business development. In 2008, he founded Rex Bio and successfully developed an antibody treatment for pancreatic cancer.
  • 강상욱 연구개발 부사장님 사진 Sang-Uk Kang

    Senior Vice President,
    Research & Development
    Ph.D.

    more
    Sang-Uk Kang serves as Senior Vice President of Research and Development. After receiving his Ph.D. in Pharmacy at Seoul National University, he had post-doctoral training at the National Cancer Institute, in US in the area of anti-cancer drugs and antibiotics. Sang-Uk had been involved in discovery of anti-cancer and hepatitis C drugs in Rexahn and Sequoia, biotech companies located in Maryland. Prior to joining Bridge Biotherapeutics, he served as General Manager in new business development, medicinal chemistry, and CMC at Chemizon (now CMG Pharmaceuticals), Bukwang Pharmaceuticals, and Yuyu Pharmaceuticals.
  • 이광희 연구 부사장 사진 Gwanghee Lee

    Senior Vice President,
    Translational Research
    Ph.D.

    more
    Gwanghee Lee serves as Senior Vice President and Head of Translational Research. After receiving his B.S. and M.S. from Seoul National University, he earned a Ph.D. in Life Science from Washington University in St. Louis and postdoctoral training at the National Institute of Health and Genentech in the U.S. Prior to joining Bridge Biotherapeutics. He served as Project Leader of anti-cancer pipelines and Director of Korea Research Institute in Sanofi.
  • 박택상 경영지원 본부장 사진 Taeksang Park

    Vice President,
    Chief Financial Officer
    AICPA

    more
    Prior to joining Bridge Biotherapeutics, Taeksang served as Manager of Finance Team at KT Commerce for 10 years where he was in charge of accounting, tax, funding, and internal controls. He also led overseas business/investment, IPO, IR, KOSDAQ registration planning, business valuation, and stock issuance at S-TEC System and Kukil Paper.

Board of Directors

  • James Jungkue Lee

    Bridge Biotherapeutics,
    CEO

  • Sang-Uk Kang

    Bridge Biotherapeutics,
    Senior Vice President,
    R&D

  • Gwanghee Lee

    Bridge Biotherapeutics,
    Senior Vice President,
    Translational Research

  • Taeksang Park

    Bridge Biotherapeutics,
    Vice President,
    Chief Financial Officer

  • JASON JUNGHWE KOO

    LB Investment,
    Managing Director

  • Robert Lee

    SV Investment,
    Senior Review Board

  • Jiwoong Chun

    KTB Network,
    Manager

  • Sung-Wuk Kim

    Hanall Biopharma,
    Vice Chairman

  • Christopher Kim

    NovatioVentures,
    Managing Director

아이콘

Development Networks

Bridge Biotherapeutics, Inc. has established cooperation networks with leading domestic and overseas discovery and development service providers such as Wuxi Apptec, Q-Best Bio, KCRN and Celerion for development of novel therapeutics.

PARTNER 협력사
CRO & CDMO 이미지

  • LEARN MORE ABOUT US
    페이스북 트위터 링크드인
  • CONTACT INFORMATION

    HQ: Suite 903-2, Bldg B, Innovalley, 253 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 13486 Republic of Korea
    US Office: Bridge Biotherapeutics, Inc. in JLABS@TMC, 2450 Holcombe Blvd. Houston, TX 77021, USA

    Director, Jong-jin Lim (jong-jin.lim@bridgebiorx.com)
    Manager, Joengbin Ahn (Joengbin.ahn@bridgebiorx.com)